메뉴 건너뛰기




Volumn 15, Issue 2, 2017, Pages 313-319

Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan

Author keywords

Adverse event; AR axis targeted agents; mCRPC; Progression free survival; Response

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; ENZALUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

EID: 84979567684     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.06.010     Document Type: Article
Times cited : (33)

References (20)
  • 1
  • 2
    • 84943797330 scopus 로고    scopus 로고
    • Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
    • 2 Chi, K., Hotte, S.J., Joshua, A.M., et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 26 (2015), 2044–2056.
    • (2015) Ann Oncol , vol.26 , pp. 2044-2056
    • Chi, K.1    Hotte, S.J.2    Joshua, A.M.3
  • 3
    • 84901231924 scopus 로고    scopus 로고
    • Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel
    • 3 Fitzpatrick, J.M., Bellmunt, J., Fizazi, K., et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 50 (2014), 1617–1627.
    • (2014) Eur J Cancer , vol.50 , pp. 1617-1627
    • Fitzpatrick, J.M.1    Bellmunt, J.2    Fizazi, K.3
  • 4
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • 4 Tannock, I.F., de Wit, R., Berry, W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    de Wit, R.2    Berry, W.R.3
  • 5
    • 4744337716 scopus 로고    scopus 로고
    • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    • 5 Petrylak, D.P., Tangen, C.M., Hussain, M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004), 1513–1520.
    • (2004) N Engl J Med , vol.351 , pp. 1513-1520
    • Petrylak, D.P.1    Tangen, C.M.2    Hussain, M.H.3
  • 6
    • 84866948935 scopus 로고    scopus 로고
    • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    • 6 Fizazi, K., Scher, H.I., Molina, A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992.
    • (2012) Lancet Oncol , vol.13 , pp. 983-992
    • Fizazi, K.1    Scher, H.I.2    Molina, A.3
  • 7
    • 84921846878 scopus 로고    scopus 로고
    • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
    • 7 Ryan, C.J., Smith, M.R., Fizazi, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
    • (2015) Lancet Oncol , vol.16 , pp. 152-160
    • Ryan, C.J.1    Smith, M.R.2    Fizazi, K.3
  • 8
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • 8 Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
    • (2012) N Engl J Med , vol.367 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 9
    • 84904871070 scopus 로고    scopus 로고
    • Enzalutamide in metastatic prostate cancer before chemotherapy
    • 9 Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
    • (2014) N Engl J Med , vol.371 , pp. 424-433
    • Beer, T.M.1    Armstrong, A.J.2    Rathkopf, D.E.3
  • 10
    • 84922516195 scopus 로고    scopus 로고
    • A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy
    • 10 Satoh, T., Uemura, H., Tanabe, K., et al. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Jpn J Clin Oncol 44 (2014), 1206–1215.
    • (2014) Jpn J Clin Oncol , vol.44 , pp. 1206-1215
    • Satoh, T.1    Uemura, H.2    Tanabe, K.3
  • 11
    • 84922527136 scopus 로고    scopus 로고
    • A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study)
    • 11 Matsubara, N., Uemura, H., Satoh, T., et al. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Clin Oncol 44 (2014), 1216–1226.
    • (2014) Jpn J Clin Oncol , vol.44 , pp. 1216-1226
    • Matsubara, N.1    Uemura, H.2    Satoh, T.3
  • 12
    • 84973411823 scopus 로고    scopus 로고
    • Efficacy and safety profile of enzalutamide for Japanese patients with castration-resistant prostate cancer
    • 12 Yamasaki, M., Yuasa, T., Yamamoto, S., et al. Efficacy and safety profile of enzalutamide for Japanese patients with castration-resistant prostate cancer. Anticancer Res 36 (2016), 361–365.
    • (2016) Anticancer Res , vol.36 , pp. 361-365
    • Yamasaki, M.1    Yuasa, T.2    Yamamoto, S.3
  • 13
    • 44449147748 scopus 로고    scopus 로고
    • Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan
    • 13 Naito, S., Tsukamoto, T., Koga, H., et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol 38 (2008), 365–372.
    • (2008) Jpn J Clin Oncol , vol.38 , pp. 365-372
    • Naito, S.1    Tsukamoto, T.2    Koga, H.3
  • 14
    • 84942988298 scopus 로고    scopus 로고
    • Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
    • 14 Nozawa, M., Mukai, H., Takahashi, S., et al. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol 20 (2015), 1026–1034.
    • (2015) Int J Clin Oncol , vol.20 , pp. 1026-1034
    • Nozawa, M.1    Mukai, H.2    Takahashi, S.3
  • 15
    • 41949104346 scopus 로고    scopus 로고
    • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    • 15 Scher, H.I., Halabi, S., Tannock, I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008), 1148–1159.
    • (2008) J Clin Oncol , vol.26 , pp. 1148-1159
    • Scher, H.I.1    Halabi, S.2    Tannock, I.3
  • 16
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    • 16 Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 17
    • 84919338396 scopus 로고    scopus 로고
    • Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer
    • 17 Auchus, R.J., Yu, M.K., Nguyen, S., et al. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 19 (2014), 1231–1240.
    • (2014) Oncologist , vol.19 , pp. 1231-1240
    • Auchus, R.J.1    Yu, M.K.2    Nguyen, S.3
  • 18
    • 84922248732 scopus 로고    scopus 로고
    • Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status
    • 18 Azad, A.A., Eigl, B.J., Leibowitz-Amit, R., et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 67 (2015), 441–447.
    • (2015) Eur Urol , vol.67 , pp. 441-447
    • Azad, A.A.1    Eigl, B.J.2    Leibowitz-Amit, R.3
  • 19
    • 84924328268 scopus 로고    scopus 로고
    • Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
    • 19 Nadal, R., Zhang, Z., Rahman, H., et al. Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 74 (2014), 1560–1568.
    • (2014) Prostate , vol.74 , pp. 1560-1568
    • Nadal, R.1    Zhang, Z.2    Rahman, H.3
  • 20
    • 84902077478 scopus 로고    scopus 로고
    • External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone
    • 20 Ravi, P., Mateo, J., Lorente, D., et al. External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. Eur Urol 66 (2014), 8–11.
    • (2014) Eur Urol , vol.66 , pp. 8-11
    • Ravi, P.1    Mateo, J.2    Lorente, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.